BOSTON--(BUSINESS WIRE)--Dana-Farber Cancer Institute today announced several senior executive and clinical leadership appointments.
Dorothy Puhy, who has served as chief financial officer and assistant treasurer at Dana-Farber since 1994, has been named executive vice president and chief operating officer. Karen Bird, senior vice president for finance, will succeed Puhy as chief financial officer and assistant treasurer.
In her new role, Puhy will help direct Dana-Farber’s ongoing strategy development and the prioritization of strategic initiatives. This will include ensuring that the corporate and infrastructure resources fully support the clinical and research enterprises. Puhy also will oversee finance, information systems, human resources, strategic planning, facilities, clinical business development, network operations, and external affairs.
Bird, who has held several finance positions at Dana-Farber beginning in 1999, will be responsible for leading the development of Dana-Farber’s financial strategy, including forecasting and budgeting, and managing the corporate finance functions. She also will staff the finance, audit and investment committees of Dana-Farber’s Board.
“During the past 10-15 years, Dana-Farber has undergone significant changes to meet the expanding demand for its cancer care services and the growth of its research programs,” said Edward J. Benz, Jr., MD, president of Dana-Farber. “These appointments will enable us to respond to the many systemic and financial changes that are expected to affect how health care is provided in the next decade.”
Dana-Faber also announced the following clinical leadership appointments:
Lawrence Shulman, MD, will direct the newly created Department of Regional Strategy Development, expanding on his previous role of director of Network Development. He also has been appointed director of the just-established Center for Global Cancer Medicine. Shulman will assume the role of chief of staff, succeeding Stephen Sallan, MD, who will become chief of staff emeritus.
Craig Bunnell, MD, MPH, MBA, has been promoted to chief medical officer, a role previously held by Shulman. Bunnell, formerly the associate chief medical officer, will lead clinical initiatives that support standardization of clinical practice and drive performance excellence.
Joseph Jacobson, MD, chief quality officer, will now be responsible for helping direct Dana-Farber’s patient safety and quality improvement initiatives in addition his focus on quality and outcomes.
Dana-Farber Cancer Institute (www.dana-farber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center, designated a comprehensive cancer center by the National Cancer Institute. It provides adult cancer care with Brigham and Women’s Hospital as Dana-Farber/Brigham and Women’s Cancer Center and it provides pediatric care with Boston Children’s Hospital as Dana-Farber/Children’s Hospital Cancer Center. Dana-Farber is the top ranked cancer center in New England, according to U.S. News & World Report, and one of the largest recipients among independent hospitals of National Cancer Institute and National Institutes of Health grant funding. Follow Dana-Farber on Twitter: @danafarber or Facebook: facebook.com/danafarbercancerinstitute.